Entity

Time filter

Source Type

Heidelberg, Germany

The German Cancer Research Center , is a national cancer research center based in Heidelberg, Germany. It is a member of the Helmholtz Association of German Research Centres, the largest scientific organization in Germany. Wikipedia.


Patent
University of Heidelberg and German Cancer Research Center | Date: 2014-07-18

The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.


The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.


Patent
German Cancer Research Center | Date: 2015-11-30

The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.


Patent
German Cancer Research Center | Date: 2014-01-06

Described is a chimerical adenovirus-parvovirus vector characterized in that it comprises the entire parvovirus genome inserted into a adenovirus genome, wherein: (a) the adenovirus genome is characterized by deletion of E1 and E3, and (b) the biological activity of the parvoviral protein NS, preferably NS1, is reduced or eliminated.


Patent
University of Heidelberg and German Cancer Research Center | Date: 2015-04-30

Provided is a novel method for the early detection and/or discrimination of cancer and anti-cancer agents for the prevention or early treatment of cancer. In particular, the method relates to the determination of levels of circulating miRNAs in breast cancer patients, both primary and metastatic. Furthermore, kits, devices, pharmaceutical compositions as well as methods related thereto are described.

Discover hidden collaborations